Cardiopulmonary Stress Testing Systems Market Size

Cardiopulmonary Stress Testing Systems Market Analysis

The cardiopulmonary stress testing systems market was anticipated to record a CAGR of nearly 4.6% during the forecast period.

The COVID-19 pandemic largely impacted healthcare systems worldwide. For instance, data from the National Institute of Health, published in February 2021, suggested that the COVID-19 pandemic did not change the clinical profile of patients referred to exercise testing. In addition, performing exercise testing wearing a facemask is feasible, with no influence on functional capacity and clinical results. Therefore, such studies indicate that the pandemic did not have a significant impact on the market studied. However, the study from PubMed, published in December 2021, suggested that circulatory impairment, abnormal ventilatory pattern, and myalgic encephalomyelitis/chronic fatigue syndrome are common in patients with post-acute sequelae of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (PASC). The dysfunctional breathing, resting hypocapnia, and ME/CFS may contribute to symptoms. There was an increasing need for cardiopulmonary stress testing equipment to assess cardiac stress. Thus, such factors indicate that there was a great impact of the COVID-19 pandemic on the market's growth.

Key factors propelling the market's growth include the increasing prevalence of cardiovascular diseases and rising healthcare expenditure across the world.

Cardiovascular diseases are posing immense pressure on the global healthcare industry. For instance, the data published by the European Heart network in 2021 reported that, in the European Union, more than 60 million people live with cardiovascular disease and close to 13 million new cases of cardiovascular diseases are diagnosed every year, demanding the adoption of stress testing procedures for early diagnosis of heart diseases.

Rising R&D studies proving the efficiency of cardiopulmonary stress tests in detecting cardiopulmonary conditions may further boost the market's growth. For instance, a study from the National Institute of Health, published in May 2022, suggested that selected cardiopulmonary exercise testing (CPET) parameters relate to the severity of angina symptoms and quality of life. Oxygen-pulse plateau detects the severity of myocardial ischemia. Thus, the advantages of early diagnosis of heart diseases with stress tests may help decrease the mortality rate associated with these diseases, thereby boosting the market.

The adoption of key strategies, such as mergers and acquisitions, by key players to expand the product portfolios and geographical presence may further drive the market's growth. For instance, in September 2021, SunTech Medical Inc. completed the acquisition of Meditech Kft, a manufacturer of ambulatory blood pressure monitors (ABPM) and ECG Holter devices based in Budapest, Hungary. This acquisition may allow SunTech to leverage the two companies' expert knowledge of blood pressure (BP) to bring better BP solutions to customers for monitoring cardiac stress.

However, stringent regulations laid out by the regulatory bodies, more challenges during the development stage, and expensive testing procedures are expected to hinder the market's growth during the forecast period.